3 recruiting. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Torvutatug samrotecan: new trials by email Literature Review of Torvutatug samrotecan trials Research Report on Torvutatug samrotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer | Phase 3 | Recruiting | AstraZeneca | 600 | 2026-09-24 | 2026-10-16 |
| Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 950 | 2026-09-16 | 2026-10-01 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 622 | 2023-06-05 | 2026-10-05 |
Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma of Lung (1) · Endometrial Neoplasms (1)
AstraZeneca (3)
Australia (3) · Canada (3) · China (3) · Germany (3) · Japan (3) · South Korea (3) · Spain (3) · Taiwan (3) · United States (3) · Brazil (2) · India (2) · Israel (2) · Italy (2) · Thailand (2) · Argentina (1)